Skip to main content

Table 1 Patients’ characteristics (n = 454)

From: Diabetes and beta-adrenergic blockage are risk factors for metastatic prostate cancer

Age at radical prostatectomy (years)
 Mean/±SD/median/IQR 65.3/6.7/66.0/61.0–70.0
PSA at radical prostatcetomy (ng/ml)
 Mean/±SD/median/IQR 13.8/24.4/8.6/5.6–14.4
Gleason score at biopsy (n)
 % (n/total)  
 8–10 25.9 (118/454)
 7 62.3 (283/454)
 6 11.7 (53/454)
Gleason score at radical prostatectomy (n)
 % (n/total)  
 8–10 21.2 (96/454)
 7 60.6 (275/454)
 6 18.3 (83/454)
T stage at biopsy (n)
 % (n/total)  
 4 1.9 (9/454)
 3 36.8 (167/454)
 2 61.2 (278/454)
T stage at radical prostatectomy (n)
 % (n/total)  
 4 0.7 (3/454)
 3 34.8 (158/454)
 2 64.3 (292/454)
CAPRA score at biopsy (n)
 % (n/total)  
 6–10 (high risk) 41.4 (188/454)
 3–5 (intermediate risk) 39.8 (181/454)
 1–2 (low risk) 18.5 (85/454)
Positive lymph nodes (N+) at radical prostatectomy (n)
 % (n/total) 21.3 (97/545)
Positive surgical margin (R+) at radical prostatectomy (n)
 % (n/total) 29.3 (133/454)
  1. PSA prostate specific antigen, CAPRA Cancer of the Prostate Risk Assessment